AbbVie Inc

ABBV

New York Stock Exchange. Currency in USD

163.06 -2.93 ( -1.77% )

Real time prices: December 09

Market Cap.
288.37B
Beta (5Y monthly)
0.67
Price/Earnings
12.13
EPS (TTM)
13.50
Forward Dividend
5.92 (3.58%)
Ex-Dividend Date
Jan 13, 2023
Volume
4.64M
1y Target Est.
159.66
Day's Range
162.81
-
167.75
52 Week's Range
125.20
-
175.91

Historical Summary

Performance
EPS growth
Share Buybacks

About AbbVie Inc

Sector
Healthcare
Industry
Drug Manufacturers-General
Website
https://www.abbvie.com
Exchange
New York Stock Exchange (XNYS)
Shares Outstanding
1.77B
Employees
50000
Address
1 North Waukegan Road, North Chicago, IL, United States, 60064-6400
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Latest news

Relative Strength Found Within These 3 Medical Stocks
Relative Strength Found Within These 3 Medical Stocks

The Zacks Medical sector has modestly outperformed the S&P 500 over the last three months,...
By Zacks Investment Research - 4 days ago

New Investor? Buy These 2 Growth Stocks
New Investor? Buy These 2 Growth Stocks

A well-diversified portfolio is the key to investing!
By The Motley Fool - 4 days ago

Is AbbVie Stock a Smart Contrarian Pick for 2023?
Is AbbVie Stock a Smart Contrarian Pick for 2023?

The pharma giant's story won't be over with anticipated sales declines for its top-selling drug.
By The Motley Fool - 4 days ago

Here's How to Prepare Your Portfolio for 2023
Here's How to Prepare Your Portfolio for 2023

Efforts now could result in gains next year and beyond.
By The Motley Fool - 5 days ago

Stocks To Watch: Oil Plays, Lowe's, Southwest Airlines And Lululemon In Focus
Stocks To Watch: Oil Plays, Lowe's, Southwest Airlines And Lululemon In Focus

Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview...
By Seeking Alpha - 6 days ago

3 Stocks to Buy Hand Over Fist in December
3 Stocks to Buy Hand Over Fist in December

These stocks could be big winners.
By The Motley Fool - 6 days ago

Why Is Pfizer (PFE) Up 6.5% Since Last Earnings Report?
Why Is Pfizer (PFE) Up 6.5% Since Last Earnings Report?

Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a...
By Zacks Investment Research - 1 week ago

S&P 500's Best Dividend Aristocrats
S&P 500's Best Dividend Aristocrats

Investors looking for stability and payout growth should look closer at Dividend Aristocrat stocks.
By The Motley Fool - 1 week ago